INOVIQ Ltd Annual Report 2022

61 Annual Report 2022 22 AUDITOR’S REMUNERATION For the year ended 30 June 2022 $ For the year ended 30 June 2021 $ Amounts received or due and receivable by the Company’s auditors Grant Thornton for: - Auditing the statutory financial report of the Parent company of the Group and auditing the statutory financial reports of any controlled entity. 107,431 67,000 107,431 67,000 23 RELATED PARTY DISCLOSURES Other related party transactions (a) Wholly Owned Group Transactions Details of interests in controlled entities are set out in Note 24. (b) Ultimate Parent Company INOVIQ Limited is the ultimate legal Australian holding Company. (c) Transactions with Other Related Parties The Company does not have any transactions with other related parties. 24 CONTROLLED ENTITIES Consolidated entities of INOVIQLtd Country of Incorporation Equity Interest held% 30 June 2022 30 June 2021 Sienna Cancer Diagnostics Limited Australia 100 100 INOVIQ Inc. (formerly Sienna Cancer Diagnostics Inc.) U.S.A. 100 100 BARD1AG SA Switzerland 100 100 25 EVENTS SUBSEQUENT TO BALANCE DATE The following announcements were made via the ASX announcement platform since the end of the reporting period: – On 21 July 2022, the Company announced that it had engaged US-based Percorso Life Sciences LLC (Percorso) under a Services Agreement to provide contract sales and logistics services, accelerating the commercial roll-out of INOVIQ’s EXO-NET research products in the USA. At the date of this report, other than that outlined above, there have been no matters or circumstances that have arisen since the end of the period which significantly, or may significantly effect: – The Group’s operations in future years; – The results of those operations in future years; or – The Group’s state of affairs in future years.

RkJQdWJsaXNoZXIy MjE2NDg3